Amy DuRoss, Co-Founder & CEO, Vineti, San Francisco, CA, highlights that despite the exciting pace of scientific discovery within the field of cell and gene therapy, it is now important for the industry to implement standardized and streamlined processes and technologies in order to support advancement and manufacturing scale out, while ensuring patient safety and minimizing costs. She describes a range of challenges that need to be addressed including the standardization of chain of identity and product labelling across different territories. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.